MHB088C for Injection

DRUG4 trials

Sponsors

Minghui Pharmaceutical Pty Ltd, Qilu Pharmaceutical Co., Ltd., Minghui Pharmaceutical (Hangzhou) Ltd

Conditions

Advanced Malignant Solid TumorAdvanced or Metastatic Solid TumorsAdvanced/Metastatic Solid TumorsSmall Cell Lung Cancer Extensive Stage

Phase 1

Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors

Not yet recruitingNCT05652855

Minghui Pharmaceutical Pty LtdAdvanced or Metastatic Solid Tumors

Start: 2023-01-23End: 2026-07-31Target: 48Updated: 2023-01-09

Study of MHB088C for Patients With Advanced Solid Malignant Tumors

RecruitingNCT07102004

Qilu Pharmaceutical Co., Ltd.Advanced/Metastatic Solid Tumors

Start: 2023-06-20End: 2027-07-31Target: 515Updated: 2025-08-03

A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors

RecruitingNCT07126665

Minghui Pharmaceutical (Hangzhou) LtdAdvanced Malignant Solid Tumor

Start: 2025-09-18End: 2031-08-31Target: 116Updated: 2025-11-18

Phase 3

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

RecruitingNCT06954246

Qilu Pharmaceutical Co., Ltd.Small Cell Lung Cancer Extensive Stage

Start: 2025-06-04End: 2028-04-30Target: 450Updated: 2025-06-18

Related Papers

Safety and efficacy of QLC5508 (MHB088C) in heavily-treated patients with metastatic castration-resistant prostate cancer: Updated data from a phase 1/2 trial.

Journal of Clinical Oncology2026-05-27